» Articles » PMID: 26988912

Loss of MiR-449a in ERG-associated Prostate Cancer Promotes the Invasive Phenotype by Inducing SIRT1

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Mar 19
PMID 26988912
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Epigenetic regulation by SIRT1, a multifaceted NAD+-dependent protein deacetylase, is one of the most common factors modulating cellular processes in a broad range of diseases, including prostate cancer (CaP). SIRT1 is over-expressed in CaP cells, however the associated mechanism is not well understood. To identify whether specific microRNAs might mediate this linkage, we have screened a miRNA library for differential expression in ERG-associated CaP tissues. Of 20 differentially and significantly expressed miRNAs that distinguish ERG-positive tumors from ERG-negative tumors, we find miR-449a is highly suppressed in ERG-positive tumors. We establish that SIRT1 is a direct target of miR-449a and is also induced by ERG in ERG-associated CaP. Our data suggest that attenuation of miR-449a promotes the invasive phenotype of the ERG-positive CaP in part by inducing the expression of SIRT1 in prostate cancer cells. Furthermore, we also find that suppression of SIRT1 results in a significant reduction in ERG expression in ERG-positive CaP cells, indicating a feed-back regulatory loop associated with ERG, miR-449a and SIRT1. We also report that ERG suppresses p53 acetylation perhaps through miR-449a-SIRT1 axis in CaP cells. Our findings provide new insight into the function of miRNAs in regulating ERG-associated CaP. Thus, miR-449a activation or SIRT1 suppression may represent new therapeutic opportunity for ERG-associated CaP.

Citing Articles

Molecular Sentinels: Unveiling the Role of Sirtuins in Prostate Cancer Progression.

Chouhan S, Muhammad N, Usmani D, Khan T, Kumar A Int J Mol Sci. 2025; 26(1.

PMID: 39796040 PMC: 11720558. DOI: 10.3390/ijms26010183.


A Critical Review on microRNAs as Prognostic Biomarkers in Laryngeal Carcinoma.

Komitova K, Dimitrov L, Stancheva G, Kyurkchiyan S, Petkova V, Dimitrov S Int J Mol Sci. 2025; 25(24.

PMID: 39769234 PMC: 11676902. DOI: 10.3390/ijms252413468.


miR-449a: A Promising Biomarker and Therapeutic Target in Cancer and Other Diseases.

Barati T, Mirzaei Z, Ebrahimi A, Shekari Khaniani M, Mansoori Derakhshan S Cell Biochem Biophys. 2024; 82(3):1629-1650.

PMID: 38809350 DOI: 10.1007/s12013-024-01322-9.


The Mechanistic Roles of Sirtuins in Breast and Prostate Cancer.

Onyiba C, Scarlett C, Weidenhofer J Cancers (Basel). 2022; 14(20).

PMID: 36291902 PMC: 9600935. DOI: 10.3390/cancers14205118.


Study on the role of SLC14A1 gene in biochemical recurrence of prostate cancer.

Ye B, Ding K, Li K, Zhu Q Sci Rep. 2022; 12(1):17064.

PMID: 36257969 PMC: 9579171. DOI: 10.1038/s41598-022-20775-7.


References
1.
Boysen G, Barbieri C, Prandi D, Blattner M, Chae S, Dahija A . SPOP mutation leads to genomic instability in prostate cancer. Elife. 2015; 4. PMC: 4621745. DOI: 10.7554/eLife.09207. View

2.
Zeng Y, Yi R, Cullen B . MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003; 100(17):9779-84. PMC: 187842. DOI: 10.1073/pnas.1630797100. View

3.
Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H . The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J. 2013; 280(9):2105-16. DOI: 10.1111/febs.12236. View

4.
Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan A . Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015; 7:129. PMC: 4683719. DOI: 10.1186/s13073-015-0252-1. View

5.
Byles V, Zhu L, Lovaas J, Chmilewski L, Wang J, Faller D . SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012; 31(43):4619-29. PMC: 4157820. DOI: 10.1038/onc.2011.612. View